The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

NCT01874756 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

95

Enrollment

OTHER

Sponsor class

Stopped Funding ended

Conditions

Schizophrenia

Interventions

DRUG: LY500307 150mg
DRUG: LY500307 75mg
DRUG: Placebo
DRUG: LY500307 25mg

Sponsor

Indiana University

Collaborators

[object Object]